Targeting RNA to Transform Glioblastoma Treatment
MD Anderson Cancer Center is developing first‑of‑its‑kind RNA‑targeting therapies for glioblastoma (GBM). By focusing on the powerful role of non‑coding RNAs, MD Anderson researchers are exploring a new therapeutic strategy that shows remarkable promise in patient‑derived tumor models and could pave the way for a new class of GBM treatments.